Company profile
Atavistik Bio, Inc.
Privately held: no public share price (Cambridge, MA clinical-stage biotech; privately held, most recently closed a $120M Series B in Dec 2025 (Nextech Invest, The Column Group, Regeneron Ventures, Lux Capital). Not present in the company roster. Sources: https://clinicaltrials.gov/study/NCT07038369 ; https://api.gleif.org/api/v1/lei-records/2549000CDYS5YH6XDR52 ; https://api.gleif.org/api/v1/lei-records/984500EC7LEQEU100570 ; https://www.globenewswire.com/news-release/2025/12/18/3207561/0/en/Atavistik-Bio-Raises-120-Million-Series-B-Financing-to-Advance-the-Development-of-Selective-Allosteric-Small-Molecule-Therapeutics-for-the-Treatment-of-Hereditary-Hemorrhagic-Telan.html ; https://atavistikbio.com/companynews/atavistik-bio-announces-60-million-series-a-financing-to-advance-genetically-validated-targets-in-metabolic-diseases-and-cancer/ Entity resolved by asset-pipeline-v2.)
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | AKT1 E17K (allosteric inhibitor)Small molecule | HR+/HER2- Breast Cancer HR+/HER2- Metastatic Breast Cancer |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.